Deus Technologies got the nod from the FDA to begin selling its RapidScreen RS-2000 to assist in the detection of early-stage lung cancer. The computer-assisted detection system digitizes and analyzes chest radiographs to identify regions of interest
Deus Technologies got the nod from the FDA to begin selling its RapidScreen RS-2000 to assist in the detection of early-stage lung cancer. The computer-assisted detection system digitizes and analyzes chest radiographs to identify regions of interest that may have features associated with early-stage lung cancer. The system uses image enhancement and pattern recognition techniques to locate suspicious areas that may warrant a second review by a radiologist. Deus developed the software using thousands of existing chest images as training data sets. The software contains elements of artificial neural networks and fuzzy logic technology.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.